| Title |
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
|
|---|---|
| Published in |
CNS Drugs, January 2019
|
| DOI | 10.1007/s40263-018-0601-x |
| Pubmed ID | |
| Authors |
Holly Green, Panagiota Tsitsi, Ioanna Markaki, Dag Aarsland, Per Svenningsson |
| Abstract |
Cognitive impairment is highly prevalent in patients with Parkinson's disease (PD) and causes adverse health outcomes. Novel procognitive therapies are needed to address this unmet need. It is now established that there is an increased risk of dementia in patients with type 2 diabetes mellitus (T2DM) and, moreover, T2DM and PD may have common underlying biological mechanisms. As such, T2DM medications are emerging as potential therapies in the context of PD dementia (PDD). In this review, we provide an update on pathophysiological mechanisms underlying cognitive impairments and PDD, focusing on diabetes-related pathways. Finally, we have conducted a review of ongoing clinical trials in PD patients with dementia, highlighting the multiple pharmacological mechanisms that are targeted to achieve cognitive enhancement. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 82 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 15% |
| Student > Master | 10 | 12% |
| Student > Ph. D. Student | 9 | 11% |
| Researcher | 7 | 9% |
| Unspecified | 6 | 7% |
| Other | 12 | 15% |
| Unknown | 26 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 15% |
| Biochemistry, Genetics and Molecular Biology | 9 | 11% |
| Neuroscience | 6 | 7% |
| Unspecified | 6 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 13 | 16% |
| Unknown | 32 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2019.
All research outputs
#2,993,320
of 23,125,690 outputs
Outputs from CNS Drugs
#261
of 1,319 outputs
Outputs of similar age
#72,843
of 437,840 outputs
Outputs of similar age from CNS Drugs
#2
of 16 outputs
Altmetric has tracked 23,125,690 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,319 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,840 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.